Anti-Obesity Medications and Investigational Agents

[madman]

Fig. 9. Early versus late weight management intervention: Illustrative consequences. Illustrative potential comparative outcomes for early versus delayed intervention in the evaluation and management of pre-obesity or obesity [84,213–221]. One of the objectives of early pharmacologic intervention for pre-obesity/obesity is to prevent the onset and complications of adiposopathic and fat mass consequences such as diabetes mellitus, hypertension, dyslipidemia, sleep apnea, arthritis, and depression (as well as other adverse health consequences of obesity such as cardiovascular disease and cancer). Lack of early intervention may lead to one or more of these complications, resulting in polypharmacy and the need to follow multiple disease-oriented guidelines.

 

[madman]

Chart 2 Estimated degree of mean weight reduction associated with anti-obesity medications, as well as the percent achievement of weight reduction 5, 10%, 15%, and 20%.

 

[madman]

Chart 3 Summary of findings and weight reduction in the tirzepatide SURPASS studies for the treatment of type 2 diabetes mellitus and cardiovascular disease and SURMOUNT program for obesity.